EPHX2 and cardiovascular disorder: 16−19 Although only a few sEH inhibitorshave made it to clinical stages, numerous preclinical studies haveunveiled the broad therapeutic potential of sEH inhibitors againstvarious inflammation-related diseases, including neurodegenerative,metabolic, and cardiovascular disorders.7